Gemcitabine induced hemolytic uremic syndrome: Underestimated?

Gemcitabine induced hemolytic uremic syndrome

BACKGROUND Gemcitabine is frequently used for the treatment of many cancers. Not infrequently it leads to development of hemolytic uremic syndrome, presenting with hemolytic anemia, acute kidney injury and occasionally peripheral edema, livedo reticularis and digital necrosis. CASE REPORT A 78 year old man with non-small cell lung cancer developed uremic syndrome following treatment with mult...

Gemcitabine-associated hemolytic-uremic syndrome.

BACKGROUND Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported. METHODS A case is presented of a 45-year-old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation. A mini-review of the literature based on a MEDLINE search follows. RESULTS Including our own...

Gemcitabine-associated Hemolytic-uremic Syndrome: a Case Report

Division of Nephrology, Department of Medicine, Department of Pathology*, Changhua Christian Hospital, Changhua, Taiwan Received: August, 2003 Revised: October, 2003 Accepted: January, 2004 Address reprint request to: Yao-Ko Wen, M.D., Division of Nephrology, Department of Medicine, Changhua Christian Hospital, 135 Nansiao St., Changhua 500, Taiwan Tel: (04) 7238595 ext 3991 Fax: 728923304 E-ma...

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition

Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature

Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, an...